| First Author | Barham W | Year | 2013 |
| Journal | Cancer Discov | Volume | 3 |
| Issue | 11 | Pages | 1286-301 |
| PubMed ID | 23921231 | Mgi Jnum | J:206992 |
| Mgi Id | MGI:5553441 | Doi | 10.1158/2159-8290.CD-13-0138 |
| Citation | Barham W, et al. (2013) Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov 3(11):1286-301 |
| abstractText | Synovial sarcoma is an aggressive soft-tissue malignancy of children and young adults, with no effective systemic therapies. Its specific oncogene, SYT-SSX (SS18-SSX), drives sarcoma initiation and development. The exact mechanism of SYT-SSX oncogenic function remains unknown. In an SYT-SSX2 transgenic model, we show that a constitutive Wnt/beta-catenin signal is aberrantly activated by SYT-SSX2, and inhibition of Wnt signaling through the genetic loss of beta-catenin blocks synovial sarcoma tumor formation. In a combination of cell-based and synovial sarcoma tumor xenograft models, we show that inhibition of the Wnt cascade through coreceptor blockade and the use of small-molecule CK1alpha activators arrests synovial sarcoma tumor growth. We find that upregulation of the Wnt/beta-catenin cascade by SYT-SSX2 correlates with its nuclear reprogramming function. These studies reveal the central role of Wnt/beta-catenin signaling in SYT-SSX2-induced sarcoma genesis, and open new venues for the development of effective synovial sarcoma curative agents. SIGNIFICANCE: Synovial sarcoma is an aggressive soft-tissue cancer that afflicts children and young adults, and for which there is no effective treatment. The current studies provide critical insight into our understanding of the pathogenesis of SYT-SSX-dependent synovial sarcoma and pave the way for the development of effective therapeutic agents for the treatment of the disease in humans. |
